Dr. Klausner Co-Chairs Committee Preparing NAS Terrorism Report

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 3
Volume 11
Issue 3

WASHINGTON-A National Academy of Sciences (NAS) committee expects to issue a report in June on terrorism that will provide the federal government with a road map for the use of science and technology in all aspects of counterterrorism, Richard D. Klausner, MD, former National Cancer Institute (NCI) director, told ONI.

WASHINGTON—A National Academy of Sciences (NAS) committee expects to issue a report in June on terrorism that will provide the federal government with a road map for the use of science and technology in all aspects of counterterrorism, Richard D. Klausner, MD, former National Cancer Institute (NCI) director, told ONI.

Dr. Klausner and Lewis M. Branscomb, PhD, Albert Pratt Public Service Professor at Harvard University’s John F. Kennedy School of Government, co-chair the committee. About 150 outside experts and consultants are contributing to the effort, which is expected to inform the decision-making process for the fiscal year 2004 budget.

In addition to his NAS commitment, Dr. Klausner continues to pursue research part time at NCI. He resigned as director last fall after more than 6 years in the post. He originally left to head a new institute established by the Case Foundation of AOL founder Steven Case and his wife, but the Cases withdrew their commitment to the project.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content